Absence of Integrase Inhibitor-Associated Resistance Among Antiretroviral Therapy-Naïve HIV-1-Infected Adults in Guangdong Province, China, in 2018

Lack of HIV-1 integrase inhibitor resistances among 392 antiretroviral-naïve subjects in a tertiary care hospital in Beijing, China

(2019) Lifeng Liu et al.   AIDS

Prevalence of Primary Drug Resistance Against HIV-1 Integrase Inhibitors in Canada

(2018) Hezhao Ji et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Primary resistance to integrase strand transfer inhibitors in patients infected with diverse HIV-1 subtypes in sub-Saharan Africa

(2018) Seth C Inzaule et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

HIV-1 integrase inhibitor resistance among treatment naïve patients in the West of Scotland

(2017) A. Bradley-Stewart et al.   JOURNAL OF CLINICAL VIROLOGY

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

(2017) Joel Gallant et al.   LANCET

HIV drug resistance levels in adults failing first-line antiretroviral therapy in an urban and a rural setting in South Africa

(2016) TM Rossouw et al.   HIV MEDICINE

HIV-1 drug resistance and resistance testing

(2016) Dana S. Clutter et al.   INFECTION GENETICS AND EVOLUTION

Differences among HIV-1 subtypes in drug resistance against integrase inhibitors

(2016) Ying-Shan Han et al.   INFECTION GENETICS AND EVOLUTION

HIV-1 Group O Resistance Against Integrase Inhibitors

(2015) Agnès Depatureaux et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Primary resistance to integrase strand-transfer inhibitors in Europe: Table 1.

(2015) M. Casadellà et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

HIV-1 genotypic drug resistance testing: digging deep, reaching wide?

(2015) Kristel Van Laethem et al.   Current Opinion in Virology

Lack of resistance to integrase inhibitors among antiretroviral-naive subjects with primary HIV-1 infection, 2007–2013

(2014) Joanne D Stekler et al.   ANTIVIRAL THERAPY

Molecular dynamics simulation studies of the wild type and E92Q/N155H mutant of Elvitegravir-resistance HIV-1 integrase

(2014)   Interdisciplinary Sciences-Computational Life Sciences

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial

(2013) François Raffi et al.   LANCET INFECTIOUS DISEASES

Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials

(2013) Joseph J Eron et al.   LANCET INFECTIOUS DISEASES

Efficacy of Raltegravir Versus Efavirenz When Combined With Tenofovir/ Emtricitabine in Treatment-Naïve HIV-1–Infected Patients: Week-192 Overall and Subgroup Analyses From STARTMRK

(2012) Edwin DeJesus et al.   HIV CLINICAL TRIALS

Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient

(2011) Sarita D Boyd et al.   ANTIVIRAL THERAPY

Long-term Treatment With Raltegravir or Efavirenz Combined With Tenofovir/Emtricitabine for Treatment-Naive Human Immunodeficiency Virus-1–Infected Patients: 156-Week Results From STARTMRK

(2011) Jürgen K. Rockstroh et al.   CLINICAL INFECTIOUS DISEASES

HIV-1 Integrase Inhibitor Resistance and Its Clinical Implications

(2011) Jose-Luis Blanco et al.   JOURNAL OF INFECTIOUS DISEASES

Absence of Primary Integrase Resistance Mutations in HIV Type 1-Infected Patients in Venezuela

(2010) Héctor R. Rangel et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Recombination Rate and Selection Strength in HIV Intra-patient Evolution

(2010) Richard A. Neher et al.   PLoS Computational Biology

A genotypic assay for the amplification and sequencing of integrase from diverse HIV-1 group M subtypes

(2008) Kristel Van Laethem et al.   JOURNAL OF VIROLOGICAL METHODS